Current FDA drug shortages
This page indexes the U.S. FDA drug-shortage records that currently carry an active (current) status. It is a regulatory finding aid, not medical advice, and it does not suggest substitutes.
What "current" means here
A current shortage is one the FDA records as active — that is, the supply of the product is recorded as not meeting demand at the time of the source data. These are the entries with the most immediate operational relevance, because they describe supply constraints that may still be in effect. On this page the status is taken directly from the FDA's public shortage data and normalised to the single value "current"; we do not infer activity that the source does not state.
Because current shortages are by definition the most time-sensitive entries, the caution about data currency matters most here. The list reflects the state of the data at the most recent ingestion run, and the live FDA record can change between runs as shortages are updated or resolved. Always confirm the current status against the official FDA source before relying on it for any planning decision, and treat this page strictly as a pointer to that authoritative record.
Current shortage records
The active shortage records in the indexed dataset are listed below, most recently updated first. Each links to its own record page, which lays out the product, company, presentation, availability text and dates as regulatory data fields and links onward to the official FDA source.
| Record | Type | Date |
|---|---|---|
| Bumetanide Injection | 2 reporting companies | 2026-08-21 |
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet | 8 reporting companies | 2026-08-20 |
| Cromolyn Sodium Concentrate | Mylan Specialty, A Viatris Company | 2026-08-20 |
| Dexamethasone Sodium Phosphate Injection | Mylan Institutional, A Viatris Company | 2026-08-20 |
| Dexmedetomidine Hydrochloride Injection | 6 reporting companies | 2026-08-20 |
| Etomidate Injection | Mylan Institutional, A Viatris Company | 2026-08-20 |
| Lisdexamfetamine Dimesylate Capsule | 6 reporting companies | 2026-08-20 |
| Remifentanil Hydrochloride Injection | Mylan Institutional, A Viatris Company | 2026-08-20 |
| Rifampin Injection | Mylan Institutional, A Viatris Company | 2026-08-20 |
| Rocuronium Bromide Injection | 4 reporting companies | 2026-08-20 |
| Methylphenidate Hydrochloride Tablet, Extended Release | 5 reporting companies | 2026-08-19 |
| Technetium Tc-99m Pyrophosphate Kit Injection | Curium US LLC | 2026-08-19 |
| Atropine Sulfate Injection | 3 reporting companies | 2026-08-18 |
| Bupivacaine Hydrochloride Injection | Onesource Specialty Pte Ltd | 2026-08-18 |
| Carboplatin Injection | 3 reporting companies | 2026-08-18 |
| Clindamycin Phosphate Injection | 3 reporting companies | 2026-08-18 |
| Conivaptan Hydrochloride Injection | Cumberland Pharmaceuticals Inc. | 2026-08-18 |
| Dextrose Monohydrate 50% Injection | Amphastar Pharmaceuticals, Inc. | 2026-08-18 |
| Furosemide Injection | 3 reporting companies | 2026-08-18 |
| Ketorolac Tromethamine Injection | 2 reporting companies | 2026-08-18 |
| Lidocaine Hydrochloride Injection | 2 reporting companies | 2026-08-18 |
| Lorazepam Injection | Amphastar Pharmaceuticals, Inc. | 2026-08-18 |
| Methylprednisolone Acetate Injection | 2 reporting companies | 2026-08-18 |
| Metronidazole Injection | Inforlife SA | 2026-08-18 |
| Midazolam Hydrochloride Injection | 2 reporting companies | 2026-08-18 |
| Morphine Sulfate Injection | Amphastar Pharmaceuticals, Inc. | 2026-08-18 |
| Quinapril Hydrochloride Tablet | Lupin Pharmaceuticals, Inc. | 2026-08-18 |
| Rifampin Capsule | 2 reporting companies | 2026-08-18 |
| Ropivacaine Hydrochloride Injection | Inforlife SA | 2026-08-18 |
| Sodium Bicarbonate Injection | 2 reporting companies | 2026-08-18 |
| Amino Acid Injection | 2 reporting companies | 2026-08-17 |
| Clonazepam Tablet | 3 reporting companies | 2026-08-17 |
| Dextrose Monohydrate 10% Injection | 2 reporting companies | 2026-08-17 |
| Dextrose Monohydrate 5% Injection | 2 reporting companies | 2026-08-17 |
| Dextrose Monohydrate 70% Injection | Otsuka Icu Medical LLC | 2026-08-17 |
| Dobutamine Hydrochloride Injection | Baxter Healthcare | 2026-08-17 |
| Dopamine Hydrochloride Injection | Baxter Healthcare | 2026-08-17 |
| Heparin Sodium Injection | Baxter Healthcare | 2026-08-17 |
| Hydromorphone Hydrochloride Injection | Teva Pharmaceuticals Usa, Inc. | 2026-08-17 |
| Ifosfamide Injection | Baxter Healthcare | 2026-08-17 |
| Liraglutide Injection | Novo Nordisk, Inc. | 2026-08-17 |
| Lisdexamfetamine Dimesylate Tablet, Chewable | Novadoz Pharmaceuticals LLC | 2026-08-17 |
| Methotrexate Sodium Injection | 2 reporting companies | 2026-08-17 |
| Peginterferon Alfa-2a Injection | Pharmaand Gmbh (pharma&) | 2026-08-17 |
| Penicillin G Benzathine Injection | Laboratorios Atral | 2026-08-17 |
| Riluzole Oral Suspension | Edw Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | 2026-08-17 |
| Sterile Water Injection | Medefil, Inc. | 2026-08-17 |
| Sterile Water Irrigant | 2 reporting companies | 2026-08-17 |
One entry per shortage
The list above holds one entry per shortage, not one per reported package line. The FDA's machine-readable feed publishes a separate line for every affected presentation and every company that has filed a report, so a single active shortage can appear there many times over. Those lines are grouped here by the product identity the agency uses to head the entry — the generic name as published, including the form in which the product is supplied — and each shortage gets exactly one address. Where a shortage is reported by more than one company, the count of reporting companies is shown in place of a single firm name, and all of them are named on the shortage's own page alongside the individual presentations they reported.
That address does not encode the status, so an entry keeps the same URL when the FDA moves it from current to resolved. Nothing about the underlying data is lost in the grouping: every shortage page reproduces each of its source lines with the reporting company, presentation, package NDC and the agency's own availability text, so any line can be verified individually at the official source.
Why current shortages matter operationally
Current shortages are the entries with the most direct bearing on day-to-day operations in the health system. Hospital and health-system pharmacies use the FDA's shortage tracking to anticipate which products may be difficult to obtain, to plan their purchasing, and to coordinate with group purchasing organisations and wholesalers. Manufacturers and distributors watch the same data to understand where supply pressure is concentrated. For all of these audiences, the value of a current-shortage index is speed: being able to see, in one place, which products the FDA currently records as in short supply, by whom they are reported, and when each entry was last updated.
This page provides exactly that index and nothing more. It reports the regulatory supply signal — product, company, status and dates — and links to the authoritative FDA record for each entry. It deliberately stops short of any clinical content. It does not say how important a product is, does not suggest what might be used instead, and does not advise any course of action, because those are professional decisions that depend on the full clinical picture and belong with qualified practitioners. The site's role is to help you find and date the official record quickly, then hand you to the regulator's copy.
What each current-shortage record contains
Each record page for a current shortage presents the same regulatory fields as the rest of the shortages section: the generic and brand names where available, the reporting company, the normalised status, the affected presentation, the FDA's availability text as a data field, and the initial-posting and last-updated dates. Because these entries are active, the last-updated date is especially worth attention — it indicates how recently the FDA's record was touched, which is your best on-page cue to how current the information is before you confirm it at the source. For the definitions of these fields and statuses, see the regulatory intelligence glossary, and for the data lineage see the methodology and FDA data sources pages.
Related views
For the full explanation of how shortages are tracked and what each status means, return to the drug shortages hub. The regulatory intelligence glossary defines the terminology, and the methodology and FDA data sources pages describe where the data comes from and its limitations.
Source & provenance
- Official source
- https://www.accessdata.fda.gov/scripts/drugshortages/
- Source dataset
- openFDA Drug Shortages API
- Publication date
- Not available
- Ingested
- 2026-08-22
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.